Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Linnea Koller"'
Autor:
Manjiri Pawaskar, Elvira Schmidt, Gary S. Marshall, Jaime Fergie, Elizabeth Richardson, Louise Parks Saldutti, Se Li, Monika Neumann, Linnea Koller, Barbara Kuter
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 18, Iss 1, Pp 1-7 (2022)
M-M-R®II (M-M-R II) is routinely used in many countries at 12–15 months with a second dose at 4 to 6 years of age. However, the vaccine may need to be administered at other ages due to delays in the immunization schedule or in certain situations s
Externí odkaz:
https://doaj.org/article/92e3bb86aa0e48e0b44dd8ccc515fd4b
Autor:
Barbara J. Kuter, Elvira Schmidt, Elizabeth Richardson, Jaime Fergie, Louise Parks Saldutti, Monika Neumann, Manjiri Pawaskar, Gary S. Marshall, Linnea Koller, Se Li
Publikováno v:
Human Vaccines & Immunotherapeutics. 18:1-7
M-M-R®II (M-M-R II) is routinely used in many countries at 12–15 months with a second dose at 4 to 6 years of age. However, the vaccine may need to be administered at other ages due to delays in th...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6ed43bd3201f1f450c7366a0dd73311
https://doi.org/10.1080/21645515.2021.1933874
https://doi.org/10.1080/21645515.2021.1933874
Publikováno v:
International Journal of Technology Assessment in Health Care. 38:S94-S94
IntroductionDiagnostic testing and patient monitoring are important to diagnose potential diseases and to evaluate treatment regimens. Since diagnosis and treatment monitoring have no intrinsic effects, an economic evaluation of biomarkers is inevita
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0ea1e093c685c5ed2f7da6ae71baa1ae
https://doi.org/10.1017/s0266462322002756
https://doi.org/10.1017/s0266462322002756
Autor:
Elvira Schmidt, Manica Agrawal, Neumann Monika, Linnea Koller, Louise Parks Saldutti, Barbara J. Kuter, Se Li, Manjiri Pawaskar, Elizabeth Richardson
Publikováno v:
Open Forum Infectious Diseases
Background M-M-R® II was approved in the US in 1978 and has been used globally for over 40 years. Widespread use of M-M-R® II has resulted in important declines in incidence, morbidity, and mortality of measles, mumps, and rubella in the US and oth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8da52c512a6e921928d7c43b8665749b
http://europepmc.org/articles/PMC7777511
http://europepmc.org/articles/PMC7777511